Alcon to Acquire LENSAR for $356 Million to Strengthen Leadership in Femtosecond Laser-Assisted Cataract Surgery

According to foreign media reports, on March 24, Alcon, the global leader in ophthalmic devices, announced that it had signed a definitive merger agreement with LENSAR, Inc., planning to fully acquire this innovative company specializing in laser cataract treatment systems.

It is reported that this acquisition includes LENSAR's Ally Robotic Cataract Laser Treatment System, its proprietary Streamline software technology platform, and traditional laser surgery systems. After the acquisition, these technologies will strengthen Alcon's product portfolio in the field of Femtosecond Laser-Assisted Cataract Surgery (FLACS).

Under the terms of the agreement, Alcon will acquire all outstanding shares of LENSAR for $14 per share in cash, corresponding to a total valuation of approximately $356 million (approximately RMB 2.6 billion). The transaction also includes a contingent value right clause: if LENSAR products cumulatively complete 614,000 surgeries between January 1, 2026, and December 31, 2027, each share can receive an additional cash consideration of up to $2.75, potentially increasing the total transaction amount to about $430 million (approximately RMB 3.1 billion). Both parties expect the transaction to close in the second half of 2025.

ALLY Robotic Cataract Laser System Integrates World-Class Imaging and Dual-Modality Lasers, as the First and Only Tissue-Specific Laser, 4 Times Faster than Traditional Methods, Optimizing Corneal and Lens Treatment. Its Astigmatism Management Software Utilizes AI and Iris Registration to Enhance Efficiency and Effectiveness, Improving Overall Surgical Precision and Efficiency, Saving Operation Time, and Providing a Better Experience for Medical Staff and Patients.

Notably, this month, LENSAR's 3D femtosecond laser cataract system with the new oval-shaped Patient Interface (PI) has been launched in China. According to reports, the new oval PI is designed to better fit the eyelid anatomy of patients with small palpebral fissures, reducing discomfort during surgery and improving surgical success rates. With its unique design featuring a transverse oval shape and curved contact surface, the oval PI can adapt more naturally to the eyelid contour, providing patients with a more comfortable surgical experience.

Regarding this acquisition, Alcon CEO David Endicott stated, "This acquisition allows us to integrate LENSAR's unique next-generation technology and intellectual property into Alcon's market-leading innovative equipment portfolio. Leveraging our global business network, we will enable more ophthalmologists to utilize femtosecond laser technology to enhance the efficiency of cataract surgeries."

BTIG analyst Ryan Zimmerman and Isolte McMahon evaluated this transaction as a win-win for all parties. The analysts pointed out that the market penetration of LENSAR's Ally system continues to increase, with clinical feedback being one of the best cases in recent years. This acquisition further solidifies Alcon’s leading position in the cataract equipment field.

Zimmerman emphasized that this is an ideal outcome for both parties — LENSAR has won several major clients from giants like Johnson & Johnson, and this growth trend is prompting industry leaders to take strategic action, further confirming that femtosecond laser technology is gradually replacing traditional manual capsulorhexis procedures.

Editor: Mu Mian

Disclaimer: The views expressed in this article are solely those of the author and do not represent the position of Yaozhi Network. We welcome exchanges and supplements in the comment area; if you need to reproduce, please be sure to indicate the author and source of the article. If it involves the content, copyright, and other issues of the work, please leave a message on this platform, and we will handle it promptly.